
Fagron N.V.
ARSUFOTCHealthcare● Active
$27.00
+$0.47(+1.77%)
Market Cap$2.0B
P/E Ratio—
52W High$27
52W Low$20.03
Fagron N.V.(ARSUF)· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。
FMP · ARSUF · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.95B | $0.87B | $0.76B | $0.68B | $0.57B |
| Cost of Revenue | $0.81B | $0.48B | $0.43B | $0.40B | $0.33B |
| Gross Profit | $0.15B | $0.40B | $0.33B | $0.29B | $0.25B |
| Gross Margin %(computed) | 15.25% | 45.38% | 43.59% | 41.84% | 43.13% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | ($0.00B) | $0.26B | $0.22B | $0.19B | $0.16B |
| Operating Income | $0.15B | $0.13B | $0.11B | $0.10B | $0.09B |
| Operating Margin %(computed) | 15.36% | 14.99% | 14.24% | 14.32% | 15.24% |
| Interest Income | $0.00B | $0.00B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.03B | $0.03B | $0.02B | $0.01B | $0.01B |
| Income Before Tax | $0.12B | $0.10B | $0.08B | $0.09B | $0.08B |
| Income Tax Expense | $0.03B | $0.02B | $0.01B | $0.02B | $0.02B |
| Net Income | $0.09B | $0.08B | $0.07B | $0.07B | $0.06B |
| Net Margin %(computed) | 9.56% | 9.24% | 9.25% | 10.18% | 10.63% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.24 | $1.10 | $0.97 | $0.96 | $0.84 |
| Wtd Avg Shares | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B |
| EBITDA | $0.19B | $0.16B | $0.13B | $0.13B | $0.11B |
| EBITDA Margin %(computed) | 20.23% | 18.13% | 17.58% | 18.96% | 19.40% |
数据来源:Financial Modeling Prep · 最后更新:2026-06-08 · EUR · B
深入了解Fagron N.V.
关于Fagron N.V.(ARSUF)损益表
Fagron N.V.(ARSUF)损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年,ARSUF实现营收$0.95B,毛利润$0.15B(毛利率15.25%),净利润$0.09B(净利率9.56%)。
常见问题
ARSUF · 4 问Fagron N.V.(ARSUF)2025财年营收为$0.95B,同比up9.2%。
ARSUF revenueARSUF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08